ADMA Biologics, Inc.
ADMA Biologics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has established itself as a leader in the development and commercialisation of specialty biologics, particularly in the field of immunoglobulin therapies. ADMA focuses on providing innovative solutions for patients with immune deficiencies and other serious conditions, offering unique products such as its proprietary immunoglobulin, ASCENIV. This product stands out due to its high purity and specific formulation, catering to the needs of patients requiring immunotherapy. With a strong market position, ADMA Biologics has achieved significant milestones, including FDA approvals and partnerships that enhance its operational reach across North America. The company continues to drive advancements in the biologics sector, committed to improving patient outcomes through its specialised therapies.
DitchCarbon Score
How does ADMA Biologics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ADMA Biologics, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
ADMA Biologics, Inc.'s reported carbon emissions
ADMA Biologics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the company may be engaged in various climate commitments and initiatives typical within the biotechnology industry, focusing on sustainability and reducing environmental impact. As the industry increasingly prioritises climate action, ADMA Biologics may align with broader trends, although specific details on their commitments or initiatives are not provided.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
ADMA Biologics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
